Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of “Moderate Buy” by Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has been given an average recommendation of “Moderate Buy” by the sixteen brokerages that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $61.13.

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $87.00 target price on shares of Arvinas in a research report on Friday, May 17th. Wells Fargo & Company cut their price objective on shares of Arvinas from $63.00 to $60.00 and set an “overweight” rating on the stock in a research note on Thursday, May 9th. Truist Financial restated a “buy” rating and set a $65.00 target price on shares of Arvinas in a research report on Monday, March 25th. Stifel Nicolaus cut their price target on Arvinas from $72.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Finally, Wedbush reissued an “outperform” rating and issued a $57.00 price objective on shares of Arvinas in a report on Wednesday, May 8th.

Institutional Investors Weigh In On Arvinas

Institutional investors have recently added to or reduced their stakes in the stock. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Arvinas during the first quarter valued at $44,000. McGlone Suttner Wealth Management Inc. purchased a new position in Arvinas in the 4th quarter valued at about $75,000. Headlands Technologies LLC boosted its holdings in Arvinas by 393.4% in the 4th quarter. Headlands Technologies LLC now owns 2,388 shares of the company’s stock worth $98,000 after buying an additional 1,904 shares during the last quarter. Contravisory Investment Management Inc. acquired a new stake in Arvinas in the 2nd quarter worth about $185,000. Finally, Personal CFO Solutions LLC purchased a new stake in Arvinas during the 4th quarter worth approximately $206,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Trading Up 9.0 %

Shares of Arvinas stock opened at $28.62 on Friday. The firm’s 50 day simple moving average is $29.08 and its two-hundred day simple moving average is $37.10. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -4.83 and a beta of 1.98. Arvinas has a 12-month low of $13.57 and a 12-month high of $53.08.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, May 7th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.45. The firm had revenue of $25.30 million during the quarter, compared to analysts’ expectations of $32.94 million. The business’s revenue was down 22.2% on a year-over-year basis. During the same quarter last year, the business earned ($1.54) EPS. On average, sell-side analysts predict that Arvinas will post -4.08 EPS for the current fiscal year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.